Dr. Mohammad Pakravan, MD

Dr. Pakravan practices at John Sealy Hospital in Galveston, Texas, part of The University of Texas System.

Dr. Pakravan's NPI, 1609459239, was assigned on May 2, 2021. Dr. Pakravan graduated from Shahid Beheshti University of Medical Sciences in 1992. Dr. Pakravan holds Texas license 48304.

Dr. Pakravan's primary practice is John Sealy Hospital, at 301 University Boulevard, Galveston, TX 77555 in Galveston County. The practice phone is (409) 772-1011.

Dr. Pakravan's primary practice is John Sealy Hospital in Galveston, Texas, part of The University of Texas System. The medical group on file is UTMB Faculty Group Practice. Dmand AI also links Dr. Pakravan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pakravan practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Pakravan's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Pakravan's licenses on file in 2 states: Texas and Arkansas.

Dmand AI lists cataract, cataract surgery with lens implant, glaucoma, glaucoma surgery, hypertensive retinopathy, secondary membranaous cataract surgery, vision problems and visual impairment and blindness among the conditions Dr. Pakravan treats.

CMS data shows 446 Medicare services from Dr. Pakravan across 9 procedure codes in 2024, for 159 Medicare patients. Medicare paid $28,966 for them.

CMS counts 159 Medicare patients who saw Dr. Pakravan in 2024. The largest group is 65 to 74, with 76 patients. 72% of them have high blood pressure, and 68% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Pakravan's median patient age at 74, with 52% women.

In 2024, Dr. Pakravan wrote 1,245 Medicare Part D claims for 229 patients. 68% of them were for generic drugs. CMS names the drug for 1,179 of them, across 11 drugs with 11 or more claims each, at $29,417 in total drug cost. In 2023, CMS named 561 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Pakravan for performance year 2024, reported as part of a group. Dr. Pakravan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 54 procedures of cataract surgery by Dr. Pakravan, more than 65% of the clinicians it reports for that procedure.

Dmand AI links 113 papers to Dr. Pakravan, published from 2012 to 2025. 2022 was the busiest year, with 24. The most frequent topics are Intraocular Pressure, Visual Acuity and Glaucoma. Dr. Pakravan has published most often in J Neuroophthalmol. Dr. Pakravan's most frequent co-authors are Hamed Esfandiari, MD, Andrew G. Lee, MD and Elham Ghahari.

CMS Open Payments shows 22 general payments to Dr. Pakravan from 6 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 62% of the total. Abbvie Inc. paid the most, $2,221.

Dr. Pakravan graduated from Shahid Beheshti University of Medical Sciences in 1992.

Dr. Pakravan is in network with 24 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 14. Check the plan with the practice before a visit.